Skip to content

ESBE - PHARMA

Active Private limited companyfounded 1986active for 39 yearsGrand-Rue 20, 6200 ChâteletKBO/BCE: BE 0430.045.342 #10 company by equity in Châtelet, Wholesale and retail trade sector

Lifetime

25 annual accounts with figures on one time axis, 39 filings since 1987
peak of €187,634 in 2025
€187,634▲ 10.4%
peak of €113,949 in 2025
€113,949▲ 12.3%
peak of €739,799 in 2025
€739,799▲ 18.2%
€68,363▼ 5.7%
Board2 names since 2021
2 directors and 1 other
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Equity from €625,734 to €739,799

Key points

from the 2025 annual accounts

Equity

€739,799 ▲ 18.2%

ESBE - PHARMA has made a profit in every financial year since 2001.

Filings

39 annual accounts since 1987
AprilJune31 JulyOctober1990200020102020

Five of the last ten came late. The 2019 accounts came in latest, 100 days after the end of the period.

Position in the sector

€113,949

Higher net result than 95% of companies in retail trade. The sector median is €4,723, over 25,429 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,155 companies had the same profile as ESBE - PHARMA has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,155 companies, not a prediction for ESBE - PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • founderdeed of 14-02-2014
  • founderdeed of 14-02-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0430045342
changes role from manager to director Gazette deed
Capital decrease of €243,000 to €18,600 The capital fell from €261,600 to €18,600 · General meeting of 26-12-2017 · Gazette deed
Capital increase The capital rose from BEF 750,000 to BEF 750,322 · The capital rose from €18,600 to €261,600 · Founded by (founder and partner) · General meeting of 21-12-2013 · Gazette deed
All 50 events

Comparable companies

same main activity, similar in size and age
Company
ESBE - PHARMA Châtelet €808,162 €187,634 91.5% -
APOTHEEK DECALUWE Linter €821,999 €186,983 55.3% 1.2
DEMEULENAERE Roeselare €761,463 €191,568 46.4% -
APOTHEEK MOPERTINGEN Bilzen-Hoeselt €858,407 €179,855 16.2% -
APOTHEEK CANDRIES - DHOLLANDER Sint-Niklaas €862,015 €175,276 60.1% 1.3
PHARMACIE BLAIRVACQ Waremme €773,237 €173,036 -3.9% 3.8
APOTHEEK MEES HAACHT CENTRUM Haacht €767,466 €196,602 29.3% 0

These companies have the same main activity as ESBE - PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €761,000 and €862,000, founded between 1983 and 1988.

Official details

Source: KBO
Status
Active since 11-12-1986Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.033.242.2396200 Châtelet, since 13-02-1987
Financial year end
31 December
Peppol
Reachable since 13-12-2025
Company details

Annual accounts 2025

≈ €660,000estimated
€808,162▲ 15.7%
Filing
Filed on 31-07-2026, on the last day of the filing period
Financials

Insights on ESBE - PHARMA

ESBE - PHARMA files the micro format. That format states no turnover. The gross margin rose from €47,657 in 2001 to €187,634 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about ESBE - PHARMA

What is the company number of ESBE - PHARMA?
The company number of ESBE - PHARMA is 0430.045.342. The VAT number is the same number with BE in front: BE 0430.045.342.
Where is ESBE - PHARMA based?
The registered office is at Grand-Rue 20, 6200 Châtelet.Company details
What does ESBE - PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of ESBE - PHARMA?
ESBE - PHARMA is a private limited company (BV).
When was ESBE - PHARMA founded?
ESBE - PHARMA was founded on 11-12-1986.
Is ESBE - PHARMA still active?
Yes, ESBE - PHARMA is an active enterprise in the KBO register.
What is the turnover of ESBE - PHARMA?
The turnover in financial year 2025 is about €660,000. This figure is estimated from the gross margin of €187,634 and 37 comparable companies (NACE 477). It probably lies between €490,000 and €1.1m.Financials
Is ESBE - PHARMA profitable?
In financial year 2025, ESBE - PHARMA made a profit of €113,949.
Where can I find the annual accounts of ESBE - PHARMA?
ESBE - PHARMA filed 39 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ESBE - PHARMA due?
ESBE - PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.